# Audit items

One block per question. Fill your answers in `audit_sheet.csv` using the matching item_id.


---

## item_001

**Question:** What percentage of oocytes tested in the category 'Female carriers of structural rearrangements or monogenic disorders' had premeiotic aneuploidy?

**Gold answer (the benchmark's 'correct' answer):** `6.66%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 6.66%  → scored correct
- `cot`: 6.66%  → scored correct
- `agent`: 6.66%  → scored correct


---

## item_002

**Question:** How many oocytes with Simple Errors were contributed by donors in the category 'Oocyte preservation due to breast cancer'?

**Gold answer (the benchmark's 'correct' answer):** `1`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 1  → scored correct
- `cot`: 1  → scored correct
- `agent`: 1  → scored correct


---

## item_003

**Question:** What percentage of oocytes tested had Simple Errors in the category 'Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations'?

**Gold answer (the benchmark's 'correct' answer):** `0%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 0%  → scored correct
- `cot`: 0%  → scored correct
- `agent`: 0%  → scored correct


---

## item_004

**Question:** How many oocytes tested had premeiotic aneuploidy in total?

**Gold answer (the benchmark's 'correct' answer):** `25`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 25  → scored correct
- `cot`: 25  → scored correct
- `agent`: 25  → scored correct


---

## item_005

**Question:** What is the average Effect value for all entries in the table?

**Gold answer (the benchmark's 'correct' answer):** `-0.06`

**Question type:** Arithmetic (Compute)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: -0.054  → scored WRONG
- `cot`: (empty)  → scored WRONG
- `agent`: -0.053657142857142855  → scored WRONG


---

## item_006

**Question:** What is the percentage of oocytes with premeiotic aneuploidy in the category of Female fertility status unknown?

**Gold answer (the benchmark's 'correct' answer):** `14.5%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 14.5%  → scored correct
- `cot`: 14.5%  → scored correct
- `agent`: 14.5%  → scored correct


---

## item_007

**Question:** How many oocytes with Simple Errors were contributed by donors in the category of Primary/secondary female factor infertility?

**Gold answer (the benchmark's 'correct' answer):** `3`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 3  → scored correct
- `cot`: 3  → scored correct
- `agent`: 3 SE  → scored correct


---

## item_008

**Question:** What percentage of oocytes with premeiotic aneuploidy were tested in the category of Oocyte preservation due to social reasons?

**Gold answer (the benchmark's 'correct' answer):** `4.3%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 4.3%  → scored correct
- `cot`: 4.3%  → scored correct
- `agent`: 5.56%  → scored WRONG


---

## item_009

**Question:** What is the forward primer sequence for Exon 3 & Exon 4?

**Gold answer (the benchmark's 'correct' answer):** `ACGTAGTGCATACACCCTTG`

**Question type:** Cell Selection (Lookup)

**The table:**

| UGT1A1 region | Forward primer (5' 3') | Reverse primer (5' 3') |
| --- | --- | --- |
| Promoter & Exon 1 | GAAACCTAATAAAGCTCCACCTTC | TTGCTCAGCATATATCTGGGGC |
| Exon 2 | TCATTTAAAGGGACCACGCC | GGAAAAGCCAAATCTAAGGTTCC |
| Exon 3 & Exon 4 | ACGTAGTGCATACACCCTTG | GAAACAACGCTATTAAATGCTACG |
| Exon 5 | GAAACAGGTTTCCTTTCCCAAG | CAGAGGGGGCACGATACATA |

**What the models answered:**

- `baseline`: ACGTAGTGCATACACCCTTG  → scored correct
- `cot`: ACGTAGTGCATACACCCTTG  → scored correct
- `agent`: ACGTAGTGCATACACCCTTG  → scored correct


---

## item_010

**Question:** What is the reverse primer sequence for Exon 2?

**Gold answer (the benchmark's 'correct' answer):** `GGAAAAGCCAAATCTAAGGTTCC`

**Question type:** Cell Selection (Lookup)

**The table:**

| UGT1A1 region | Forward primer (5' 3') | Reverse primer (5' 3') |
| --- | --- | --- |
| Promoter & Exon 1 | GAAACCTAATAAAGCTCCACCTTC | TTGCTCAGCATATATCTGGGGC |
| Exon 2 | TCATTTAAAGGGACCACGCC | GGAAAAGCCAAATCTAAGGTTCC |
| Exon 3 & Exon 4 | ACGTAGTGCATACACCCTTG | GAAACAACGCTATTAAATGCTACG |
| Exon 5 | GAAACAGGTTTCCTTTCCCAAG | CAGAGGGGGCACGATACATA |

**What the models answered:**

- `baseline`: 'GGAAAAGCCAAATCTAAGGTTCC  → scored correct
- `cot`: GGAAAAGCCAAATCTAAGGTTCC  → scored correct
- `agent`: 'GGAAAAGCCAAATCTAAGGTTCC  → scored correct


---

## item_011

**Question:** Which region has the forward primer sequence 'GAAACCTAATAAAGCTCCACCTTC'?

**Gold answer (the benchmark's 'correct' answer):** `Promoter & Exon 1`

**Question type:** Cell Selection (Lookup)

**The table:**

| UGT1A1 region | Forward primer (5' 3') | Reverse primer (5' 3') |
| --- | --- | --- |
| Promoter & Exon 1 | GAAACCTAATAAAGCTCCACCTTC | TTGCTCAGCATATATCTGGGGC |
| Exon 2 | TCATTTAAAGGGACCACGCC | GGAAAAGCCAAATCTAAGGTTCC |
| Exon 3 & Exon 4 | ACGTAGTGCATACACCCTTG | GAAACAACGCTATTAAATGCTACG |
| Exon 5 | GAAACAGGTTTCCTTTCCCAAG | CAGAGGGGGCACGATACATA |

**What the models answered:**

- `baseline`: Promoter & Exon 1  → scored correct
- `cot`: Promoter & Exon 1  → scored correct
- `agent`: 'Promoter & Exon 1  → scored correct


---

## item_012

**Question:** What is the forward primer sequence for Exon 5?

**Gold answer (the benchmark's 'correct' answer):** `GAAACAGGTTTCCTTTCCCAAG`

**Question type:** Cell Selection (Lookup)

**The table:**

| UGT1A1 region | Forward primer (5' 3') | Reverse primer (5' 3') |
| --- | --- | --- |
| Promoter & Exon 1 | GAAACCTAATAAAGCTCCACCTTC | TTGCTCAGCATATATCTGGGGC |
| Exon 2 | TCATTTAAAGGGACCACGCC | GGAAAAGCCAAATCTAAGGTTCC |
| Exon 3 & Exon 4 | ACGTAGTGCATACACCCTTG | GAAACAACGCTATTAAATGCTACG |
| Exon 5 | GAAACAGGTTTCCTTTCCCAAG | CAGAGGGGGCACGATACATA |

**What the models answered:**

- `baseline`: GAAACAGGTTTCCTTTCCCAAG  → scored correct
- `cot`: GAAACAGGTTTCCTTTCCCAAG  → scored correct
- `agent`: 'GAAACAGGTTTCCTTTCCCAAG  → scored correct


---

## item_013

**Question:** What is the reverse primer sequence for Promoter & Exon 1?

**Gold answer (the benchmark's 'correct' answer):** `TTGCTCAGCATATATCTGGGGC`

**Question type:** Cell Selection (Lookup)

**The table:**

| UGT1A1 region | Forward primer (5' 3') | Reverse primer (5' 3') |
| --- | --- | --- |
| Promoter & Exon 1 | GAAACCTAATAAAGCTCCACCTTC | TTGCTCAGCATATATCTGGGGC |
| Exon 2 | TCATTTAAAGGGACCACGCC | GGAAAAGCCAAATCTAAGGTTCC |
| Exon 3 & Exon 4 | ACGTAGTGCATACACCCTTG | GAAACAACGCTATTAAATGCTACG |
| Exon 5 | GAAACAGGTTTCCTTTCCCAAG | CAGAGGGGGCACGATACATA |

**What the models answered:**

- `baseline`: TTGCTCAGCATATATCTGGGGC  → scored correct
- `cot`: 'TTGCTCAGCATATATCTGGGGC  → scored correct
- `agent`: 'TTGCTCAGCATATATCTGGGGC  → scored correct


---

## item_014

**Question:** What is the p-value for the gene Zinc finger protein 492?

**Gold answer (the benchmark's 'correct' answer):** `1.30E-06`

**Question type:** Cell Selection (Lookup)

**The table:**

| Expression | Probe ID | Gene Name | p-value (t-Test) | FC Signed Magnitude | Gene Symbol |
| --- | --- | --- | --- | --- | --- |
| UP | 213920_at | Cut-like 2 (Drosophila) | 6.38E-06 | 2.77 | CUTL2 |
| UP | 215532_x_at | Zinc finger protein 492 | 1.30E-06 | 2.44 | ZNF492 |
| UP | 214735_at | Phosphoinositide-binding protein PIP3-E | 1.19E-04 | 2.4 | PIP3-E |
| UP | 220232_at | Stearoyl-CoA desaturase 4, biosynthesis of monounsaturated fatty acids from saturated fatty acids | 2.35E-05 | 2.34 | SCD4 |
| UP | 204730_at | Regulating synaptic membrane exocytosis 3 (RIMS3), Ca2+-binding C2 domain | 2.02E-04 | 2.22 | RIMS3 |
| UP | 216153_x_at | Reversion-inducing-cysteine-rich protein with kazal motifs | 1.92E-04 | 2.21 | RECK |
| UP | 216511_s_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 1.04E-03 | 2.19 | TCF7L2(TCF4) |
| UP | 215182_x_at | mRNA; cDNA DKFZp586E121 (from clone DKFZp586E121) | 9.75E-04 | 2.12 | unknown |
| UP | 216037_x_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 9.49E-05 | 2.04 | TCF7L2(TCF4) |
| UP | 21580l_at | mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615) | 7.57E-05 | 2.01 | unknown |
| UP | 222249_at | KIAA1651 protein | 1.03E-03 | 2.01 | unknown |
| DOWN | 209687_at | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor I) | 2.79E-03 | -2.01 | CXCL12 |
| DOWN | 206662_at | Glutaredoxin (thioltransferase) | 2.70E-04 | -2.04 | GLRX |
| DOWN | 207768_at | Early growth response 4 | 8.53E-03 | -2.06 | EGR4 |
| DOWN | 208650_s_at | CD24 antigen | 3.43E-04 | -2.21 | CD24 |
| DOWN | 203235_at | (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I | 3.05E-03 | -2.25 | THOP |
| DOWN | 214432_at | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 2.43E-04 | -2.28 | ATPIA3 |
| DOWN | 202802_at | Deoxyhypusine synthase | 3.39E-03 | -2.34 | DHPS |
| DOWN | 205626_s_at | Calbindin I, 28 kDa | 5.36E-05 | -2.46 | CALBI |
| DOWN | 219389_at | Hypothetical protein FLJ 10052 | 6.06E-05 | -2.71 | FLJ10052 |
| DOWN | 266_s_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 3.91E-04 | -2.75 | CD24 |
| DOWN | 207307_at | 5-hydroxytryptamine(serotonin) receptor 2C | 1.49E-03 | -2.82 | HTR2C |
| DOWN | 208651_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.25E-05 | -2.92 | CD24 |
| DOWN | 206935_at | Protocadherin 8 | 1.46E-06 | -2.92 | PCDH8 |
| DOWN | 216379_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.17E-06 | -2.97 | CD24 |
| DOWN | 209771_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 2.30E-05 | -3.23 | CD24 |

**What the models answered:**

- `baseline`: 1.30E-06  → scored correct
- `cot`: 1.30E-06  → scored correct
- `agent`: 1.30E-06  → scored correct


---

## item_015

**Question:** What is the Fold Change (FC) magnitude for the gene ATPase, Na+/K+ transporting, alpha 3 polypeptide?

**Gold answer (the benchmark's 'correct' answer):** `-2.28`

**Question type:** Cell Selection (Lookup)

**The table:**

| Expression | Probe ID | Gene Name | p-value (t-Test) | FC Signed Magnitude | Gene Symbol |
| --- | --- | --- | --- | --- | --- |
| UP | 213920_at | Cut-like 2 (Drosophila) | 6.38E-06 | 2.77 | CUTL2 |
| UP | 215532_x_at | Zinc finger protein 492 | 1.30E-06 | 2.44 | ZNF492 |
| UP | 214735_at | Phosphoinositide-binding protein PIP3-E | 1.19E-04 | 2.4 | PIP3-E |
| UP | 220232_at | Stearoyl-CoA desaturase 4, biosynthesis of monounsaturated fatty acids from saturated fatty acids | 2.35E-05 | 2.34 | SCD4 |
| UP | 204730_at | Regulating synaptic membrane exocytosis 3 (RIMS3), Ca2+-binding C2 domain | 2.02E-04 | 2.22 | RIMS3 |
| UP | 216153_x_at | Reversion-inducing-cysteine-rich protein with kazal motifs | 1.92E-04 | 2.21 | RECK |
| UP | 216511_s_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 1.04E-03 | 2.19 | TCF7L2(TCF4) |
| UP | 215182_x_at | mRNA; cDNA DKFZp586E121 (from clone DKFZp586E121) | 9.75E-04 | 2.12 | unknown |
| UP | 216037_x_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 9.49E-05 | 2.04 | TCF7L2(TCF4) |
| UP | 21580l_at | mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615) | 7.57E-05 | 2.01 | unknown |
| UP | 222249_at | KIAA1651 protein | 1.03E-03 | 2.01 | unknown |
| DOWN | 209687_at | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor I) | 2.79E-03 | -2.01 | CXCL12 |
| DOWN | 206662_at | Glutaredoxin (thioltransferase) | 2.70E-04 | -2.04 | GLRX |
| DOWN | 207768_at | Early growth response 4 | 8.53E-03 | -2.06 | EGR4 |
| DOWN | 208650_s_at | CD24 antigen | 3.43E-04 | -2.21 | CD24 |
| DOWN | 203235_at | (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I | 3.05E-03 | -2.25 | THOP |
| DOWN | 214432_at | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 2.43E-04 | -2.28 | ATPIA3 |
| DOWN | 202802_at | Deoxyhypusine synthase | 3.39E-03 | -2.34 | DHPS |
| DOWN | 205626_s_at | Calbindin I, 28 kDa | 5.36E-05 | -2.46 | CALBI |
| DOWN | 219389_at | Hypothetical protein FLJ 10052 | 6.06E-05 | -2.71 | FLJ10052 |
| DOWN | 266_s_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 3.91E-04 | -2.75 | CD24 |
| DOWN | 207307_at | 5-hydroxytryptamine(serotonin) receptor 2C | 1.49E-03 | -2.82 | HTR2C |
| DOWN | 208651_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.25E-05 | -2.92 | CD24 |
| DOWN | 206935_at | Protocadherin 8 | 1.46E-06 | -2.92 | PCDH8 |
| DOWN | 216379_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.17E-06 | -2.97 | CD24 |
| DOWN | 209771_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 2.30E-05 | -3.23 | CD24 |

**What the models answered:**

- `baseline`: 2.28  → scored WRONG
- `cot`: 2.28  → scored WRONG
- `agent`: 2.28  → scored WRONG


---

## item_016

**Question:** What is the Gene Symbol for the gene with a p-value of 8.53E-03?

**Gold answer (the benchmark's 'correct' answer):** `EGR4`

**Question type:** Cell Selection (Lookup)

**The table:**

| Expression | Probe ID | Gene Name | p-value (t-Test) | FC Signed Magnitude | Gene Symbol |
| --- | --- | --- | --- | --- | --- |
| UP | 213920_at | Cut-like 2 (Drosophila) | 6.38E-06 | 2.77 | CUTL2 |
| UP | 215532_x_at | Zinc finger protein 492 | 1.30E-06 | 2.44 | ZNF492 |
| UP | 214735_at | Phosphoinositide-binding protein PIP3-E | 1.19E-04 | 2.4 | PIP3-E |
| UP | 220232_at | Stearoyl-CoA desaturase 4, biosynthesis of monounsaturated fatty acids from saturated fatty acids | 2.35E-05 | 2.34 | SCD4 |
| UP | 204730_at | Regulating synaptic membrane exocytosis 3 (RIMS3), Ca2+-binding C2 domain | 2.02E-04 | 2.22 | RIMS3 |
| UP | 216153_x_at | Reversion-inducing-cysteine-rich protein with kazal motifs | 1.92E-04 | 2.21 | RECK |
| UP | 216511_s_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 1.04E-03 | 2.19 | TCF7L2(TCF4) |
| UP | 215182_x_at | mRNA; cDNA DKFZp586E121 (from clone DKFZp586E121) | 9.75E-04 | 2.12 | unknown |
| UP | 216037_x_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 9.49E-05 | 2.04 | TCF7L2(TCF4) |
| UP | 21580l_at | mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615) | 7.57E-05 | 2.01 | unknown |
| UP | 222249_at | KIAA1651 protein | 1.03E-03 | 2.01 | unknown |
| DOWN | 209687_at | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor I) | 2.79E-03 | -2.01 | CXCL12 |
| DOWN | 206662_at | Glutaredoxin (thioltransferase) | 2.70E-04 | -2.04 | GLRX |
| DOWN | 207768_at | Early growth response 4 | 8.53E-03 | -2.06 | EGR4 |
| DOWN | 208650_s_at | CD24 antigen | 3.43E-04 | -2.21 | CD24 |
| DOWN | 203235_at | (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I | 3.05E-03 | -2.25 | THOP |
| DOWN | 214432_at | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 2.43E-04 | -2.28 | ATPIA3 |
| DOWN | 202802_at | Deoxyhypusine synthase | 3.39E-03 | -2.34 | DHPS |
| DOWN | 205626_s_at | Calbindin I, 28 kDa | 5.36E-05 | -2.46 | CALBI |
| DOWN | 219389_at | Hypothetical protein FLJ 10052 | 6.06E-05 | -2.71 | FLJ10052 |
| DOWN | 266_s_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 3.91E-04 | -2.75 | CD24 |
| DOWN | 207307_at | 5-hydroxytryptamine(serotonin) receptor 2C | 1.49E-03 | -2.82 | HTR2C |
| DOWN | 208651_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.25E-05 | -2.92 | CD24 |
| DOWN | 206935_at | Protocadherin 8 | 1.46E-06 | -2.92 | PCDH8 |
| DOWN | 216379_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.17E-06 | -2.97 | CD24 |
| DOWN | 209771_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 2.30E-05 | -3.23 | CD24 |

**What the models answered:**

- `baseline`: EGR4  → scored correct
- `cot`: EGR4  → scored correct
- `agent`: EGR4  → scored correct


---

## item_017

**Question:** Which gene has the highest Fold Change (FC) magnitude in this table?

**Gold answer (the benchmark's 'correct' answer):** `CD24`

**Question type:** Identification (Lookup)

**The table:**

| Expression | Probe ID | Gene Name | p-value (t-Test) | FC Signed Magnitude | Gene Symbol |
| --- | --- | --- | --- | --- | --- |
| UP | 213920_at | Cut-like 2 (Drosophila) | 6.38E-06 | 2.77 | CUTL2 |
| UP | 215532_x_at | Zinc finger protein 492 | 1.30E-06 | 2.44 | ZNF492 |
| UP | 214735_at | Phosphoinositide-binding protein PIP3-E | 1.19E-04 | 2.4 | PIP3-E |
| UP | 220232_at | Stearoyl-CoA desaturase 4, biosynthesis of monounsaturated fatty acids from saturated fatty acids | 2.35E-05 | 2.34 | SCD4 |
| UP | 204730_at | Regulating synaptic membrane exocytosis 3 (RIMS3), Ca2+-binding C2 domain | 2.02E-04 | 2.22 | RIMS3 |
| UP | 216153_x_at | Reversion-inducing-cysteine-rich protein with kazal motifs | 1.92E-04 | 2.21 | RECK |
| UP | 216511_s_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 1.04E-03 | 2.19 | TCF7L2(TCF4) |
| UP | 215182_x_at | mRNA; cDNA DKFZp586E121 (from clone DKFZp586E121) | 9.75E-04 | 2.12 | unknown |
| UP | 216037_x_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 9.49E-05 | 2.04 | TCF7L2(TCF4) |
| UP | 21580l_at | mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615) | 7.57E-05 | 2.01 | unknown |
| UP | 222249_at | KIAA1651 protein | 1.03E-03 | 2.01 | unknown |
| DOWN | 209687_at | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor I) | 2.79E-03 | -2.01 | CXCL12 |
| DOWN | 206662_at | Glutaredoxin (thioltransferase) | 2.70E-04 | -2.04 | GLRX |
| DOWN | 207768_at | Early growth response 4 | 8.53E-03 | -2.06 | EGR4 |
| DOWN | 208650_s_at | CD24 antigen | 3.43E-04 | -2.21 | CD24 |
| DOWN | 203235_at | (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I | 3.05E-03 | -2.25 | THOP |
| DOWN | 214432_at | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 2.43E-04 | -2.28 | ATPIA3 |
| DOWN | 202802_at | Deoxyhypusine synthase | 3.39E-03 | -2.34 | DHPS |
| DOWN | 205626_s_at | Calbindin I, 28 kDa | 5.36E-05 | -2.46 | CALBI |
| DOWN | 219389_at | Hypothetical protein FLJ 10052 | 6.06E-05 | -2.71 | FLJ10052 |
| DOWN | 266_s_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 3.91E-04 | -2.75 | CD24 |
| DOWN | 207307_at | 5-hydroxytryptamine(serotonin) receptor 2C | 1.49E-03 | -2.82 | HTR2C |
| DOWN | 208651_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.25E-05 | -2.92 | CD24 |
| DOWN | 206935_at | Protocadherin 8 | 1.46E-06 | -2.92 | PCDH8 |
| DOWN | 216379_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.17E-06 | -2.97 | CD24 |
| DOWN | 209771_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 2.30E-05 | -3.23 | CD24 |

**What the models answered:**

- `baseline`: CD24  → scored correct
- `cot`: CD24  → scored correct
- `agent`: CD24  → scored correct


---

## item_018

**Question:** What is the Gene Name associated with the gene symbol THOP?

**Gold answer (the benchmark's 'correct' answer):** `Thimet oligopeptidase I`

**Question type:** Cell Selection (Lookup)

**The table:**

| Expression | Probe ID | Gene Name | p-value (t-Test) | FC Signed Magnitude | Gene Symbol |
| --- | --- | --- | --- | --- | --- |
| UP | 213920_at | Cut-like 2 (Drosophila) | 6.38E-06 | 2.77 | CUTL2 |
| UP | 215532_x_at | Zinc finger protein 492 | 1.30E-06 | 2.44 | ZNF492 |
| UP | 214735_at | Phosphoinositide-binding protein PIP3-E | 1.19E-04 | 2.4 | PIP3-E |
| UP | 220232_at | Stearoyl-CoA desaturase 4, biosynthesis of monounsaturated fatty acids from saturated fatty acids | 2.35E-05 | 2.34 | SCD4 |
| UP | 204730_at | Regulating synaptic membrane exocytosis 3 (RIMS3), Ca2+-binding C2 domain | 2.02E-04 | 2.22 | RIMS3 |
| UP | 216153_x_at | Reversion-inducing-cysteine-rich protein with kazal motifs | 1.92E-04 | 2.21 | RECK |
| UP | 216511_s_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 1.04E-03 | 2.19 | TCF7L2(TCF4) |
| UP | 215182_x_at | mRNA; cDNA DKFZp586E121 (from clone DKFZp586E121) | 9.75E-04 | 2.12 | unknown |
| UP | 216037_x_at | Transcription factor 7-like 2 (T-cell specific, HMG-box) (T-cellspecific transcription factor 4) | 9.49E-05 | 2.04 | TCF7L2(TCF4) |
| UP | 21580l_at | mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615) | 7.57E-05 | 2.01 | unknown |
| UP | 222249_at | KIAA1651 protein | 1.03E-03 | 2.01 | unknown |
| DOWN | 209687_at | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor I) | 2.79E-03 | -2.01 | CXCL12 |
| DOWN | 206662_at | Glutaredoxin (thioltransferase) | 2.70E-04 | -2.04 | GLRX |
| DOWN | 207768_at | Early growth response 4 | 8.53E-03 | -2.06 | EGR4 |
| DOWN | 208650_s_at | CD24 antigen | 3.43E-04 | -2.21 | CD24 |
| DOWN | 203235_at | (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I | 3.05E-03 | -2.25 | THOP |
| DOWN | 214432_at | ATPase, Na+/K+ transporting, alpha 3 polypeptide | 2.43E-04 | -2.28 | ATPIA3 |
| DOWN | 202802_at | Deoxyhypusine synthase | 3.39E-03 | -2.34 | DHPS |
| DOWN | 205626_s_at | Calbindin I, 28 kDa | 5.36E-05 | -2.46 | CALBI |
| DOWN | 219389_at | Hypothetical protein FLJ 10052 | 6.06E-05 | -2.71 | FLJ10052 |
| DOWN | 266_s_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 3.91E-04 | -2.75 | CD24 |
| DOWN | 207307_at | 5-hydroxytryptamine(serotonin) receptor 2C | 1.49E-03 | -2.82 | HTR2C |
| DOWN | 208651_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.25E-05 | -2.92 | CD24 |
| DOWN | 206935_at | Protocadherin 8 | 1.46E-06 | -2.92 | PCDH8 |
| DOWN | 216379_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 4.17E-06 | -2.97 | CD24 |
| DOWN | 209771_x_at | CD24 antigen (small cell lung carcinoma cluster 4 antigen) | 2.30E-05 | -3.23 | CD24 |

**What the models answered:**

- `baseline`: (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I  → scored correct
- `cot`: (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I  → scored correct
- `agent`: (small cell lung carcinoma cluster 4 antigen) Thimet oligopeptidase I  → scored correct


---

## item_019

**Question:** What is the current treatment for patient E1?

**Gold answer (the benchmark's 'correct' answer):** `Steroids`

**Question type:** Cell Selection (Lookup)

**The table:**

| Patient/sex E | Age at disease onset (years) | Age at genetic diagnosis (years) | Fever | CRP level mg/L | Cutaneous involvement | Musculo- skeletal disorders | Peripheral and central nervous system involvement | Immunologic/ haematologic involvement | Other | Current treatment | ADA2 genotypes and predicted protein alterations |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| A1/F C | 3.5 | 9 | Yes | 140 | Cutaneous vasculitis | Inflammatory myositis | Ischaemic stroke | Low IgM and IgA level; lymphopenia | Internuclear ophthalmoplaegia; hypertension; inflammatory anaemia | TNF alpha blockade | c.[1358A>G];[(972 +1_973-1), (1081 +1_1082-1)del] p. [(Tyr453Cys)];[(?)] |
| A2/F C | 1 | 7 | Yes | >5 | No | No | Paralysis of the right extrinsic third cranial nerve; cephalalgia; meningitis | Low IgM and IgA level; lymphopenia | Inflammatory anaemia | TNF alpha blockade | c.[1358A>G];[(972 +1_973-1)_(1081 +1_1082-1)del] [(Tyr453Cys)];[(?)] |
| B1/F M | 19 | 32 | No | 100 | Livedo racemosa; urticaria; Erythema nodosum | No | Convulsive attacks | ND | Uveitis; papillitis; Abdominal pain; micro renal and mesenteric aneuvrysms | IVIg; Endoxan; MTX; Imurel | c.[73G>T];{73G>T] p.[(Gly25Cys)]; [(Gly25Cys)] |
| B2/M M | 20 | 27 | Yes | >5 | Livedo racemosa; urticaria; necrosis | Arthritis; arthralgia | No | ND | Pericarditis; abdominal pain; hepatic aneuvrysms | IVIg; Endoxan; MTX; Imurel | c.[73G>T];[73G>T] p.[(Gly25Cys)]; [(Gly25Cys)] |
| C1/F C | 3 | 12 | Yes | 65 | Livedo racemosa; urticaria | Arthralgia | No | ND | Abdominal pain | TNF alpha blockade | c.[144del]; [1078A>G] p. [(Arg49Glyfs*4)]; [(Thr360Ala)] |
| D1/M C | 13 | 24 | Yes | 100 | No | Arthralgia; myalgia | Protuberantial ischaemic strokes | Low IgM level; lymphopenia | No | TNF alpha blockade | c.[506G>A]; [506G>A] p. [(Arg169Gln)]; [(Arg169Gln)] |
| E1/M C | 14 | 20 | Yes | >5 | Cutaneous vasculitis; necrosis; maculo- papular rash | Arthralgia; myalgia | Ischaemic strokes; meningitis; headaches; peripheral neuropathy | ND | Abdominal pain; pleuropericarditis | Steroids | c.[144del]; [1348G>T] p. [(Arg49Glyfs*4)]; [(Gly450Cys)] |
| F1/F M | 10 | 30 | Yes | >5 | Livedo racemosa; PAN; necrosis | Arthralgia | No | ND | No | ND | c.[1358A>G]; [1358A>G] p. [(Tyr453Cys)]; [(Tyr453Cys)] |
| G1/M C | 2 | 17 | Yes | >5 |  | No |  | ND |  |  |  |

**What the models answered:**

- `baseline`: Steroids  → scored correct
- `cot`: Steroids  → scored correct
- `agent`: Steroids  → scored correct


---

## item_020

**Question:** How many donors contributed oocytes with premeiotic aneuploidy in the category of Oocyte preservation due to breast cancer?

**Gold answer (the benchmark's 'correct' answer):** `2 donors`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 2 donors  → scored correct
- `cot`: 2 donors  → scored correct
- `agent`: 2 donors  → scored correct


---

## item_021

**Question:** What percentage of oocytes tested in the category of Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations had premeiotic aneuploidy?

**Gold answer (the benchmark's 'correct' answer):** `0%`

**Question type:** Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 0%  → scored correct
- `cot`: 0%  → scored correct
- `agent`: 0.0%  → scored correct


---

## item_022

**Question:** How many oocytes had Simple (SE) Errors in the category of Female carriers of structural rearrangements or monogenic disorders?

**Gold answer (the benchmark's 'correct' answer):** `1`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 1  → scored correct
- `cot`: 1  → scored correct
- `agent`: 1  → scored correct


---

## item_023

**Question:** What was the total number of oocytes with premeiotic aneuploidy in the table?

**Gold answer (the benchmark's 'correct' answer):** `25`

**Question type:** Summation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 25  → scored correct
- `cot`: 25  → scored correct
- `agent`: 25  → scored correct


---

## item_024

**Question:** How many donors contributed oocytes with premeiotic aneuploidy in the table overall?

**Gold answer (the benchmark's 'correct' answer):** `15 donors`

**Question type:** Counting (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 4.Oocyte preservation due to breast cancer | 2 | 10 | 5 (50%) | 2 donors | 1(SE); 4(CE) |
| 5.Female carriers of structural rearrangements or monogenic disorders (non- cancer related) | 17 | 30 | 2 (6.66%) | 2 donors | 1(SE); 1(CE) |
| 6.Females at increased risk of developing breast/ ovarian cancer due to BRCA1/2 gene mutations | 4 | 15 | 0 | 0 | 0 |
| Total | 78 | 202 | 25 (12.38%) | 15 donors | 13 (SE); 12 (CE) |

**What the models answered:**

- `baseline`: 15 donors  → scored correct
- `cot`: 15 donors  → scored correct
- `agent`: 15 donors  → scored correct


---

## item_025

**Question:** What is the Lipid species for the SNP rs201385366?

**Gold answer (the benchmark's 'correct' answer):** `LPE(22:6;0)`

**Question type:** Cell Selection (Lookup)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: LPE(22:6;0)  → scored correct
- `cot`: LPE(22:6;0)  → scored correct
- `agent`: LPE(22:6;0)  → scored correct


---

## item_026

**Question:** What is the Effect for the SNP rs534693155?

**Gold answer (the benchmark's 'correct' answer):** `1.24`

**Question type:** Cell Selection (Lookup)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: 1.24  → scored correct
- `cot`: 1.24  → scored correct
- `agent`: 1.24  → scored correct


---

## item_027

**Question:** What is the Position for the SNP rs11570891?

**Gold answer (the benchmark's 'correct' answer):** `8:19822810`

**Question type:** Cell Selection (Lookup)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: 8:19822810  → scored correct
- `cot`: 8:19822810  → scored correct
- `agent`: 8:19822810  → scored correct


---

## item_028

**Question:** What is the Gene for the SNP rs140645847?

**Gold answer (the benchmark's 'correct' answer):** `SHTN1`

**Question type:** Cell Selection (Lookup)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: SHTN1  → scored correct
- `cot`: SHTN1  → scored correct
- `agent`: SHTN1  → scored correct


---

## item_029

**Question:** What is the P value for the SNP rs10790495?

**Gold answer (the benchmark's 'correct' answer):** `2.1 x 10-8`

**Question type:** Cell Selection (Lookup)

**The table:**

| SNP | Position | Gene | Change | Ref | Alt | AF | Lipid species | Effect | SE | P |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| rs201385366 | 1:897866 | KLHL17 | Intronic | C | T | 0.019 | LPE(22:6;0) | -0.87 | 0.16 | 3.6 X 10-8 |
| rs187163948 | 1:14399146 | KAZN' | Intronic | G | A | 0.011 | TAG(53:3;0) | 0.95 | 0.17 | 3.5 10-8 |
| rs76866386# | 2:44075483 | ABCG5/8 | Intronic | T | C | 0.077 | CE(20:2;0) | -0.39 | 0.06 | 3.9 10-10 |
| rs58029241 | 2:98701245 | VWA3B | Intergenic | T | A | 0.062 | TAG(50:1;0) | 0.37 | 0.07 | 1.9 X 10-8 |
| rs13070110 | 3:21393248 | ZNF385D* | Intergenic | T | C | 0.085 | Total CER | 0.33 | 0.06 | 3.9 x 10-9 |
| rs10212439 | 3:142655053 | PAQR9 | Intergenic | T | C | 0.602 | PI(18:0;0-18:1;0) | 0.18 | 0.03 | 3.1 10-8 |
| rs13151374 | 4:8122221 | ABLIM2* | Intronic | G | A | 0.153 | TAG(50:1;0) | 0.25 | 0.04 | 3.7 X 10-8 |
| rs186689484 | 4:97033701 | PDHA2* | Intergenic | G | A | 0.051 | TAG(52:4;0) | -0.40 | 0.07 | 4.2 X 10-8 |
| rs543895501 | 6:74120350 | DDX43* | Intronic | C | T | 0.013 | Total LPC | 0.87 | 0.16 | 2.9 X 10-8 |
| rs4896307 | 6:138297840 | TNFAIP3* | Intergenic | C | T | 0.216 | PCO(16:1;0-16:0;0) | -0.23 | 0.04 | 3.3 X 10-8 |
| rs534693155 | 7:101081274 | COL26A1 | Intronic | A | G | 0.010 | LPC(16:1;0) | 1.24 | 0.23 | 3.9 X 10-8 |
| rs10281741 | 7:157793122 | PTPRN2* | Intronic | G | C | 0.225 | TAG(54:6;0) | 0.21 | 0.04 | 2.2 X 10-8 |
| rs1478898 | 8:11395079 | BLK | Intronic | G | A | 0.440 | PC(16:0;0-16:0;0) | 0.17 | 0.03 | 2.5 x 10-8 |
| rs11570891 | 8:19822810 | LPL | Intronic | C | T | 0.075 | TAG(52:3;0) | -0.33 | 0.06 | 2.9 X 10-8 |
| rs146717710 | 9:137549865 | COL5A1* | Intronic | C | T | 0.011 | PC(16:0;0-16:1;0) | -1.03 | 0.19 | 2.8 X 10-8 |
| rs140645847 | 10:118863255 | SHTN1 | Intronic | G | T | 0.101 | LPE(20:4;0) | -0.32 | 0.06 | 3.3 X 10-8 |
| rs28456# | 11:61589481 | FADS2 | Intronic | A | G | 0.405 | CE(20:4;0) | -0.59 | 0.03 | 1.1 10-77 |
| rs964184 | 11:116648917 | APOA5 | Intergenic | G | C | 0.855 | TAG(52:3;0) | -0.258 | 0.045 | 9.5 X 10-9 |
| rs10790495 | 11:122198706 | MIR100HG* | Intronic | A | G | 0.590 | TAG(56:4;0) | -0.20 | 0.04 | 2.1 x 10-8 |
| rs117388573# | 12:78980665 | SYT1* | Intergenic | A | G | 0.020 | LPC(14:0;0) | -0.77 | 0.13 | 9.8 10-10 |
| rs512948 | 13:52374489 | DHRS12* | Intronic | T | C | 0.225 | LPE(18:2;0) | -0.22 | 0.04 | 1.4 X 10-8 |
| rs8008070# | 14:64233720 | SYNE2 | Intronic | A | T | 0.133 | SM(32:1;2) | 0.48 | 0.05 | 2.9 X 10-26 |
| rs3902951 | 14:69789755 | GALNT16 | Intronic | T | G | 0.361 | PEO(18:1;0-18:2;0) | 0.19 | 0.03 | 1.9 X 10-8 |
| rs35861938 | 15:45637343 | GATM | Intergenic | T | C | 0.398 | PCO(18:2;0-18:1;0) | 0.18 | 0.03 | 2.7 X 10-8 |
| rs261290# | 15:58678720 | LIPC | Intronic | T | C | 0.617 | PE(18:0;0-20:4;0) | -0.37 | 0.03 | 4.0 X 10-31 |
| rs35221977# | 16:79563576 | MAF | Intronic | G | C | 0.054 | LPC(16:0;0) | -0.46 | 0.08 | 1.3 X 10-9 |
| rs79202680 | 17:4692640 | GLTPD2 | Intronic | G | T | 0.032 | SM(34:0;2) | -0.85 | 0.09 | 3.4 X 10-22 |
| rs143203352 | 17:77293933 | RBFOX3* | Intronic | T | C | 0.024 | PC(16:0;0-18:1;0) | 0.60 | 0.11 | 3.2 X 10-8 |
| rs151223356P | 18:18627427 | ROCK1* | Intronic | A | C | 0.013 | LPC(14:0;0) | 0.97 | 0.15 | 1.9 X 10-10 |
| rs7246617# | 19:8272163 | CERS4 | Intergenic | G | A | 0.402 | SM(38:2;2) | 0.25 | 0.03 | 2.5 X 10-15 |
| rs2455069 | 19:51728641 | CD33* | Missense | A | G | 0.383 | TAG(52:5;0) | -0.19 | 0.03 | 9.3 X 10-9 |
| rs8736# | 19:54677189 | MBOAT7 | UTR | C | T | 0.388 | PI(18:0;0-20:4;0) | -0.38 | 0.03 | 9.8 X 10-28 |
| rs4374298 | 19:55738746 | TMEM86B | Synonymous | G | A | 0.166 | PEO(16:1;0-20:4;0) | -0.25 | 0.04 | 2.3 X 10-8 |
| rs364585# | 20:12962718 | SPTLC3 | Intergenic | A | G | 0.670 | Total CER | -0.20 | 0.03 | 9.1 10-10 |
| rs186680008 | 22:39754367 | SYNGR1* | Intronic | A | C | 0.015 | CE(20:3;0) | -0.81 | 0.15 | 2.6 X 10-8 |

**What the models answered:**

- `baseline`: 2.1 x 10-8  → scored correct
- `cot`: 2.1 x 10-8  → scored correct
- `agent`: '2.1 x 10-8  → scored correct


---

## item_030

**Question:** How many donors contributed oocytes with premeiotic aneuploidy in the category 'Female fertility status unknown'?

**Gold answer (the benchmark's 'correct' answer):** `6 donors`

**Question type:** Cell Selection (Lookup)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 6 donors  → scored correct
- `cot`: 6 donors  → scored correct
- `agent`: 6 donors  → scored correct


---

## item_031

**Question:** What percentage of oocytes tested in the category 'Primary/secondary female factor infertility' had premeiotic aneuploidy?

**Gold answer (the benchmark's 'correct' answer):** `12.5%`

**Question type:** Calculation (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 12.5%  → scored correct
- `cot`: 12.5%  → scored correct
- `agent`: 12.5%  → scored correct


---

## item_032

**Question:** How many oocytes had Simple (SE) Errors in the category 'Oocyte preservation due to social reasons'?

**Gold answer (the benchmark's 'correct' answer):** `1(SE)`

**Question type:** Cell Selection (Lookup)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 1  → scored correct
- `cot`: 1  → scored correct
- `agent`: 1  → scored correct


---

## item_033

**Question:** Which category had the highest percentage of oocytes with Simple (SE) Errors?

**Gold answer (the benchmark's 'correct' answer):** `Female fertility status unknown`

**Question type:** Comparison (Compute)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: Female fertility status unknown  → scored correct
- `cot`: 1. Female fertility status unknown  → scored correct
- `agent`: '1. Female fertility status unknown  → scored correct


---

## item_034

**Question:** What is the total number of oocytes tested in the category 'Primary/secondary female factor infertility'?

**Gold answer (the benchmark's 'correct' answer):** `48`

**Question type:** Cell Selection (Lookup)

**The table:**

| Classification of female partners based on reproductive histories | Total No. of donors | Total oocytes tested | Oocytes with premeiotic aneuploidy | No. of donors contributing oocytes with premeiotic aneuploidy | No. of oocytes with Simple (SE)/ Complex (CE) Errors |
| --- | --- | --- | --- | --- | --- |
| 1. Female fertility status unknown | 27 | 76 | 11 (14.5%) | 6 donors | 7(SE); 4(CE) |
| 2.Primary/secondary female factor infertility | 25 | 48 | 6 (12.5%) | 4 donors | 3(SE); 3(CE) |
| 3.Oocyte preservation due to social reasons | 3 | 23 | 1 (4.3%) | 1 donor | 1(SE) |

**What the models answered:**

- `baseline`: 48  → scored correct
- `cot`: 48  → scored correct
- `agent`: 48  → scored correct


---

## item_035

**Question:** What is the total number of variants with pre-existing personal and/or family criteria for genetic analysis in the 'Actionable genes' category?

**Gold answer (the benchmark's 'correct' answer):** `30`

**Question type:** Arithmetic (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 30 variants  → scored correct
- `cot`: 30  → scored correct
- `agent`: 30  → scored correct


---

## item_036

**Question:** What percentage of variants in the 'Non-actionable genes' category have more than one incidental variant?

**Gold answer (the benchmark's 'correct' answer):** `28%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 16.7%  → scored WRONG
- `cot`: 31.8%  → scored WRONG
- `agent`: 71.4%  → scored WRONG


---

## item_037

**Question:** How many variants in the 'Others' category have heterozygous variants of recessive conditions known before EXOMA?

**Gold answer (the benchmark's 'correct' answer):** `1`

**Question type:** Arithmetic (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 19  → scored WRONG
- `cot`: 1 variant  → scored correct
- `agent`: 19  → scored WRONG


---

## item_038

**Question:** What percentage of 'Total' variants have analysis criteria not identified by the oncologist?

**Gold answer (the benchmark's 'correct' answer):** `22.7%`

**Question type:** Percentage Calculation (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 34.6%  → scored WRONG
- `cot`: 34.6%  → scored WRONG
- `agent`: 34.5679012345679%  → scored WRONG


---

## item_039

**Question:** How many variants in the 'MITF' gene have incidental variants?

**Gold answer (the benchmark's 'correct' answer):** `4`

**Question type:** Arithmetic (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 4  → scored correct
- `cot`: 4  → scored correct
- `agent`: 4 variants  → scored correct


---

## item_040

**Question:** What is the total number of cows on farms A, B, and C?

**Gold answer (the benchmark's 'correct' answer):** `39`

**Question type:** Arithmetic (Compute)

**The table:**

| Farms | No. of cows on farm | No. of observations/ farm | Average At (days) |
| --- | --- | --- | --- |
| A | 134 | 11 | 14 |
| B | 105 | 11 | 14 |
| C | 159 | 11 | 14 |
| D | 118 | 11 | 14 |
| E | 102 | 11 | 13.6 |
| F | 133 | 10 | 15.6 |
| G | 100 | 11 | 14 |
| H | 189 | 11 | 14 |
| I | 104 | 11 | 14 |
| J | 88 | 11 | 14 |
| K | 130 | 9 | 14 |
| L | 151 | 11 | 13.9 |
| Total | 1513 | 129 | - |

**What the models answered:**

- `baseline`: 398  → scored WRONG
- `cot`: 398  → scored WRONG
- `agent`: 398 cows  → scored WRONG


---

## item_041

**Question:** What is the total number of observations for all farms in the table?

**Gold answer (the benchmark's 'correct' answer):** `129`

**Question type:** Arithmetic (Compute)

**The table:**

| Farms | No. of cows on farm | No. of observations/ farm | Average At (days) |
| --- | --- | --- | --- |
| A | 134 | 11 | 14 |
| B | 105 | 11 | 14 |
| C | 159 | 11 | 14 |
| D | 118 | 11 | 14 |
| E | 102 | 11 | 13.6 |
| F | 133 | 10 | 15.6 |
| G | 100 | 11 | 14 |
| H | 189 | 11 | 14 |
| I | 104 | 11 | 14 |
| J | 88 | 11 | 14 |
| K | 130 | 9 | 14 |
| L | 151 | 11 | 13.9 |
| Total | 1513 | 129 | - |

**What the models answered:**

- `baseline`: 129  → scored correct
- `cot`: 129  → scored correct
- `agent`: 129  → scored correct


---

## item_042

**Question:** What is the total number of variables included in non-invasive measurements?

**Gold answer (the benchmark's 'correct' answer):** `51`

**Question type:** Calculation (Compute)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 13  → scored WRONG
- `cot`: 13  → scored WRONG
- `agent`: 13  → scored WRONG


---

## item_043

**Question:** What is the total number of variables included in invasive measurements?

**Gold answer (the benchmark's 'correct' answer):** `15`

**Question type:** Calculation (Compute)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 4  → scored WRONG
- `cot`: 4  → scored WRONG
- `agent`: 15  → scored correct


---

## item_044

**Question:** What is the average number of variables included in the invasive measurements?

**Gold answer (the benchmark's 'correct' answer):** `3`

**Question type:** Calculation (Compute)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 3.75  → scored WRONG
- `cot`: 3.75  → scored WRONG
- `agent`: 3.75  → scored WRONG


---

## item_045

**Question:** What is the difference between the total number of variables in non-invasive and invasive measurements?

**Gold answer (the benchmark's 'correct' answer):** `36`

**Question type:** Calculation (Compute)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 13  → scored WRONG
- `cot`: 15  → scored WRONG
- `agent`: 42  → scored WRONG


---

## item_046

**Question:** How many variants were identified in the gene BRCA1?

**Gold answer (the benchmark's 'correct' answer):** `7`

**Question type:** Cell Selection (Lookup)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 7  → scored correct
- `cot`: 7  → scored correct
- `agent`: 7  → scored correct


---

## item_047

**Question:** What percentage of variants in BRCA2 were known before EXOMA?

**Gold answer (the benchmark's 'correct' answer):** `26.7%`

**Question type:** Calculation (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 26.7%  → scored correct
- `cot`: 26.7%  → scored correct
- `agent`: 26.7%  → scored correct


---

## item_048

**Question:** How many variants with pre-existing personal and/or family criteria for genetic analysis were identified in PALB2?

**Gold answer (the benchmark's 'correct' answer):** `2`

**Question type:** Cell Selection (Lookup)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 2  → scored correct
- `cot`: 2  → scored correct
- `agent`: 2  → scored correct


---

## item_049

**Question:** How many incidental variants were found in the gene MUTYH?

**Gold answer (the benchmark's 'correct' answer):** `NA`

**Question type:** Cell Selection (Lookup)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: N/A  → scored correct
- `cot`: N/A  → scored correct
- `agent`: N/A  → scored correct


---

## item_050

**Question:** What percentage of variants in CHEK2 were non-actionable?

**Gold answer (the benchmark's 'correct' answer):** `28.6%`

**Question type:** Calculation (Compute)

**The table:**

| Genes | Number of variants (% of all P/ LP variants identified) | Number of variants already known before EXOMA (% if relevant) | Number of variants with pre- existing personal and/or family criteria for genetic analysis, phenotype-related or not (% if relevant) | Number of variants with analysis criteria not identified by the oncologist (% if relevant) | Number of incidental variants (% if relevant) |
| --- | --- | --- | --- | --- | --- |
| Actionable | genes |  |  |  |  |
| BRCA1 | 7 (8.6) | 5/7 (71.4) | 7/7 | 0/7 | 1/7 (14.3) |
| BRCA2 | 15 (18.5) | 4/15 (26.7) | 9/15 (60.0) | 5/9 (55.6) | 2/15 (13.3) |
| PALB2 | 2 (2.5) | 0/2 | 2/2 | 1/2 | 0/2 |
| RAD51C | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| MLH1 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| MSH2 | 2 (2.5) | 1/2 | 1/2 | 0/1 | 1/2 |
| MSH6 | 2 (2.5) | 0/2 | 0/2 | N/A | 1/2 |
| APC | 1 (1.2) | 0/1 | 1/1 | 0/1 | 0/1 |
| POLD1 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| FLCN | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| NF1 | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| TP53 | 2 (2.5) | 1/2 | 2/2 | 1/2 | 0/2 |
| CDKN2A | 2 (2.5) | 2/2 | 2/2 | 0/2 | 0/2 |
| SDHB | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| SDHD | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| ATM (hom) | 1 (1.2) | 1/1 | 1/1 | 0/1 | 0/1 |
| Total | 42/81 (51.9) | 17/42 (40.5) | 30/42 (71.4) | 8/30 (26.7) | 8/42 (19.0) |
| Non-actionable | genes |  |  |  |  |
| CHEK2 | 7 (8.6) | 0/7 | 1/7 (14.3) | 0/1 | 2/7 (28.6) |
| ATM(het) | 7 (8.6) | 1/7 (14.3) | 3/7 (42.9) | 1/3 (33.3) | 2/7 (28.6) |
| BARD1 | 1 (1.2) | 0/1 | 1/1 | 1/1 | 0/1 |
| RAD50 | 1 (1.2) | 0/1 | 0/1 | N/A | 1/1 |
| MITF | 4 (4.9) | 0/4 | 0/4 | N/A | 4/4 |
| NBN | 3 (3.7) | 0/3 | 1/3 (33.3) | 0/1 | 3/3 |
| CDKN1B | 1 (1.2) | 0/1 | 1/1 | 0/1 | 1/1 |
| Total | 66/81 (81.5) | 18/66 (27.3) | 37/66 (56.1) | 10/37 (27.0) | 21/66 (31.8) |
| Others | (heterozygous variants | of recessive conditions) |  |  |  |
| MUTYH | 13 (16.0) | 1/13 (7.7) | 7/13 (53.8) | N/A | N/A |
| NTHL1 | 2 (2.5) | 0/2 | 0/2 | N/A | N/A |
| Total | 81/81 (100) | 19/81 (23.5) | 44/81 (54.3) | 10/44 (22.7) | 21/81 (26.0) |

**What the models answered:**

- `baseline`: 100%  → scored WRONG
- `cot`: 100%  → scored WRONG
- `agent`: 100%  → scored WRONG


---

## item_051

**Question:** What is the average number of observations per farm?

**Gold answer (the benchmark's 'correct' answer):** `10`

**Question type:** Calculation (Compute)

**The table:**

| Farms | No. of cows on farm | No. of observations/ farm | Average At (days) |
| --- | --- | --- | --- |
| A | 134 | 11 | 14 |
| B | 105 | 11 | 14 |
| C | 159 | 11 | 14 |
| D | 118 | 11 | 14 |
| E | 102 | 11 | 13.6 |
| F | 133 | 10 | 15.6 |
| G | 100 | 11 | 14 |
| H | 189 | 11 | 14 |
| I | 104 | 11 | 14 |
| J | 88 | 11 | 14 |
| K | 130 | 9 | 14 |
| L | 151 | 11 | 13.9 |
| Total | 1513 | 129 | - |

**What the models answered:**

- `baseline`: 10.75 observations per farm  → scored WRONG
- `cot`: 10.75  → scored WRONG
- `agent`: 10.75 observations per farm  → scored WRONG


---

## item_052

**Question:** What is the total number of cows on all farms?

**Gold answer (the benchmark's 'correct' answer):** `1513`

**Question type:** Calculation (Compute)

**The table:**

| Farms | No. of cows on farm | No. of observations/ farm | Average At (days) |
| --- | --- | --- | --- |
| A | 134 | 11 | 14 |
| B | 105 | 11 | 14 |
| C | 159 | 11 | 14 |
| D | 118 | 11 | 14 |
| E | 102 | 11 | 13.6 |
| F | 133 | 10 | 15.6 |
| G | 100 | 11 | 14 |
| H | 189 | 11 | 14 |
| I | 104 | 11 | 14 |
| J | 88 | 11 | 14 |
| K | 130 | 9 | 14 |
| L | 151 | 11 | 13.9 |
| Total | 1513 | 129 | - |

**What the models answered:**

- `baseline`: 1513  → scored correct
- `cot`: 1513  → scored correct
- `agent`: 1513 cows  → scored correct


---

## item_053

**Question:** How many equations include the variable 'Age'?

**Gold answer (the benchmark's 'correct' answer):** `14`

**Question type:** Cell Selection (Lookup)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 14  → scored correct
- `cot`: 14  → scored correct
- `agent`: 14  → scored correct


---

## item_054

**Question:** How many equations include the variable 'Blood pressure, Systolic'?

**Gold answer (the benchmark's 'correct' answer):** `4`

**Question type:** Cell Selection (Lookup)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 4  → scored correct
- `cot`: 4  → scored correct
- `agent`: 4  → scored correct


---

## item_055

**Question:** How many equations include the variable 'BMI'?

**Gold answer (the benchmark's 'correct' answer):** `11`

**Question type:** Cell Selection (Lookup)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 11  → scored correct
- `cot`: 11  → scored correct
- `agent`: 11  → scored correct


---

## item_056

**Question:** How many equations include the variable 'Fasting glucose'?

**Gold answer (the benchmark's 'correct' answer):** `5`

**Question type:** Cell Selection (Lookup)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 5  → scored correct
- `cot`: 5  → scored correct
- `agent`: 5  → scored correct


---

## item_057

**Question:** How many equations include the variable 'Height'?

**Gold answer (the benchmark's 'correct' answer):** `3`

**Question type:** Cell Selection (Lookup)

**The table:**

|  | Number of equations which include variable |
| --- | --- |
| NON-INVASIVE VARIABLES |  |
| Subjective/medical history |  |
| Age | 14 |
| Family history of diabetes | 12 |
| Prescription medication, hypertension | 9 |
| Sex | 4 |
| Race/Ethnicity | 4 |
| Hypertension | 3 |
| History of high blood glucose | 2 |
| Physical activity | 2 |
| Prescription medications, steroids | 2 |
| Smoking | 2 |
| Diet (Fruit and vegetable consumption) | 2 |
| Family history of cardiovascular disease | 1 |
| Clinical/Measured |  |
| BMI | 11 |
| Waist circumference | 10 |
| Blood pressure, Systolic | 4 |
| Height | 3 |
| Heart rate | 1 |
| INVASIVE VARIABLES |  |
| Plasma or Serum |  |
| Fasting glucose | 5 |
| High density lipoprotein | 5 |
| Triglycerides | 4 |
| Whole Blood |  |
| Hemoglobin A1C | 1 |

**What the models answered:**

- `baseline`: 3  → scored correct
- `cot`: 3  → scored correct
- `agent`: 3  → scored correct


---

## item_058

**Question:** What is the equation for LDL quantification in the LDLPuavilai study using the automated enzymatic method?

**Gold answer (the benchmark's 'correct' answer):** `TC HDL - (TG / 6)`

**Question type:** Calculation (Compute)

**The table:**

| LDLcal | Pub. year | N of subjects or specimens | Studied region | Specimen type | TG concentration characteristics | Measurement method for LDL quantification | Equations |
| --- | --- | --- | --- | --- | --- | --- | --- |
| LDLFriedwald | 1972 | 448 subjects | USA | Plasma | TG ranged 20-2502 mg/dL. | Ultracentrifugation | TC - HDL (TG / 5) |
| LDLDeLong | 1986 | 10,483 subjects | USA | Plasma or serum | 964 subjects whose TG > 400 mg/dl were included. | Ultracentrifugation | TC (HDL + 0.16 X TG) |
| LDLRao | 1988 | 196 sera | Kuwait | Serum | 33 subjects defined as high TG (> 204 mg/dL) were included. | Ultracentrifugation | TC - HDL {TG X [0.203 (0.00011 TG)]} |
| LDLHattori | 1998 | 2179 subjects | Japan | Plasma | Subjects with TG > 400 mg/dL were excluded. a | Ultracentrifugation | (0.94 TC) (0.94 HDL) 0.19 TG |
| LDLAnadaraja | 2005 | 2008 subjects | India | Plasma | 153 subjects whose TG 350 mg/dL were included. | Ultracentrifugation | (0.9 TC) (0.9 X TG / 5) - 28 |
| LDLAhmadi | 2008 | 230 sera from 115 subjects | Iran | Serum | All subjects had TG < mg/dL. a Equations were produced using data from patients with TG < 100 mg/dL. | Automated enzymatic method | (TC 1.19) (HDL / 1.1) + 1.9) 38 |
| LDLPuavilai | 2009 | 999 sera | Thailand | Serum | 80 subjects whose TG > 300 mg/dl were included. | Automated enzymatic method | TC HDL - (TG 6) |
| LDLVujovic | 2010 | 2053 subjects | Serbia | Serum | Subjects with TG > 400 mg/dL were excluded. a | Automated enzymatic method | TC HDL (TG/ 6.58) |
| LDLChen and Zhang | 2010 | 2180 subjects | China | Serum | 480 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | X 0.9 (TG X 0.1) |
| LDLde Cordova | 2013 | 10,664 subjects | Brazil | Serum | 470 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | 0.7516 X (TC HDL) |
| LDLMartin | 2013 | 1,350,908 subjects | USA | Serum | 10,124 subjects whose TG > 400 mg/dL were included. | Ultracentrifugation | (TC - HDL) - (TG / different adjustable factors) |
| LDLChoi | This study | Development cohort: 5198 sera from 4562 subjects Validation cohort 1: 2163 sera from 2086 subjects Validation cohort 2: 889 sera from 889 subjects | South Korea | Serum | 302 sera with TG > 400 mg/dL were included. 75 sera with TG > 400 mg/dL were included. All subjects had TG 200 mg/dL (Among them, 131 had TG > 400 mg/dL) | Automated enzymatic method b | TC 0.87 X HDL 0.13 TG |

**What the models answered:**

- `baseline`: TC HDL - (TG 6)  → scored correct
- `cot`: TC HDL - (TG 6)  → scored correct
- `agent`: TC HDL - (TG 6)  → scored correct


---

## item_059

**Question:** How many subjects had TG > 400 mg/dL in the LDLde Cordova study?

**Gold answer (the benchmark's 'correct' answer):** `470 subjects`

**Question type:** Calculation (Compute)

**The table:**

| LDLcal | Pub. year | N of subjects or specimens | Studied region | Specimen type | TG concentration characteristics | Measurement method for LDL quantification | Equations |
| --- | --- | --- | --- | --- | --- | --- | --- |
| LDLFriedwald | 1972 | 448 subjects | USA | Plasma | TG ranged 20-2502 mg/dL. | Ultracentrifugation | TC - HDL (TG / 5) |
| LDLDeLong | 1986 | 10,483 subjects | USA | Plasma or serum | 964 subjects whose TG > 400 mg/dl were included. | Ultracentrifugation | TC (HDL + 0.16 X TG) |
| LDLRao | 1988 | 196 sera | Kuwait | Serum | 33 subjects defined as high TG (> 204 mg/dL) were included. | Ultracentrifugation | TC - HDL {TG X [0.203 (0.00011 TG)]} |
| LDLHattori | 1998 | 2179 subjects | Japan | Plasma | Subjects with TG > 400 mg/dL were excluded. a | Ultracentrifugation | (0.94 TC) (0.94 HDL) 0.19 TG |
| LDLAnadaraja | 2005 | 2008 subjects | India | Plasma | 153 subjects whose TG 350 mg/dL were included. | Ultracentrifugation | (0.9 TC) (0.9 X TG / 5) - 28 |
| LDLAhmadi | 2008 | 230 sera from 115 subjects | Iran | Serum | All subjects had TG < mg/dL. a Equations were produced using data from patients with TG < 100 mg/dL. | Automated enzymatic method | (TC 1.19) (HDL / 1.1) + 1.9) 38 |
| LDLPuavilai | 2009 | 999 sera | Thailand | Serum | 80 subjects whose TG > 300 mg/dl were included. | Automated enzymatic method | TC HDL - (TG 6) |
| LDLVujovic | 2010 | 2053 subjects | Serbia | Serum | Subjects with TG > 400 mg/dL were excluded. a | Automated enzymatic method | TC HDL (TG/ 6.58) |
| LDLChen and Zhang | 2010 | 2180 subjects | China | Serum | 480 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | X 0.9 (TG X 0.1) |
| LDLde Cordova | 2013 | 10,664 subjects | Brazil | Serum | 470 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | 0.7516 X (TC HDL) |
| LDLMartin | 2013 | 1,350,908 subjects | USA | Serum | 10,124 subjects whose TG > 400 mg/dL were included. | Ultracentrifugation | (TC - HDL) - (TG / different adjustable factors) |
| LDLChoi | This study | Development cohort: 5198 sera from 4562 subjects Validation cohort 1: 2163 sera from 2086 subjects Validation cohort 2: 889 sera from 889 subjects | South Korea | Serum | 302 sera with TG > 400 mg/dL were included. 75 sera with TG > 400 mg/dL were included. All subjects had TG 200 mg/dL (Among them, 131 had TG > 400 mg/dL) | Automated enzymatic method b | TC 0.87 X HDL 0.13 TG |

**What the models answered:**

- `baseline`: 470  → scored correct
- `cot`: 470 subjects  → scored correct
- `agent`: 470 subjects  → scored correct


---

## item_060

**Question:** What is the equation for LDL quantification in the LDLChoi study using the automated enzymatic method?

**Gold answer (the benchmark's 'correct' answer):** `TC 0.87 X HDL 0.13 TG`

**Question type:** Calculation (Compute)

**The table:**

| LDLcal | Pub. year | N of subjects or specimens | Studied region | Specimen type | TG concentration characteristics | Measurement method for LDL quantification | Equations |
| --- | --- | --- | --- | --- | --- | --- | --- |
| LDLFriedwald | 1972 | 448 subjects | USA | Plasma | TG ranged 20-2502 mg/dL. | Ultracentrifugation | TC - HDL (TG / 5) |
| LDLDeLong | 1986 | 10,483 subjects | USA | Plasma or serum | 964 subjects whose TG > 400 mg/dl were included. | Ultracentrifugation | TC (HDL + 0.16 X TG) |
| LDLRao | 1988 | 196 sera | Kuwait | Serum | 33 subjects defined as high TG (> 204 mg/dL) were included. | Ultracentrifugation | TC - HDL {TG X [0.203 (0.00011 TG)]} |
| LDLHattori | 1998 | 2179 subjects | Japan | Plasma | Subjects with TG > 400 mg/dL were excluded. a | Ultracentrifugation | (0.94 TC) (0.94 HDL) 0.19 TG |
| LDLAnadaraja | 2005 | 2008 subjects | India | Plasma | 153 subjects whose TG 350 mg/dL were included. | Ultracentrifugation | (0.9 TC) (0.9 X TG / 5) - 28 |
| LDLAhmadi | 2008 | 230 sera from 115 subjects | Iran | Serum | All subjects had TG < mg/dL. a Equations were produced using data from patients with TG < 100 mg/dL. | Automated enzymatic method | (TC 1.19) (HDL / 1.1) + 1.9) 38 |
| LDLPuavilai | 2009 | 999 sera | Thailand | Serum | 80 subjects whose TG > 300 mg/dl were included. | Automated enzymatic method | TC HDL - (TG 6) |
| LDLVujovic | 2010 | 2053 subjects | Serbia | Serum | Subjects with TG > 400 mg/dL were excluded. a | Automated enzymatic method | TC HDL (TG/ 6.58) |
| LDLChen and Zhang | 2010 | 2180 subjects | China | Serum | 480 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | X 0.9 (TG X 0.1) |
| LDLde Cordova | 2013 | 10,664 subjects | Brazil | Serum | 470 subjects whose TG > 400 mg/dL were included. | Automated enzymatic method | 0.7516 X (TC HDL) |
| LDLMartin | 2013 | 1,350,908 subjects | USA | Serum | 10,124 subjects whose TG > 400 mg/dL were included. | Ultracentrifugation | (TC - HDL) - (TG / different adjustable factors) |
| LDLChoi | This study | Development cohort: 5198 sera from 4562 subjects Validation cohort 1: 2163 sera from 2086 subjects Validation cohort 2: 889 sera from 889 subjects | South Korea | Serum | 302 sera with TG > 400 mg/dL were included. 75 sera with TG > 400 mg/dL were included. All subjects had TG 200 mg/dL (Among them, 131 had TG > 400 mg/dL) | Automated enzymatic method b | TC 0.87 X HDL 0.13 TG |

**What the models answered:**

- `baseline`: TC 0.87 X HDL 0.13 TG  → scored correct
- `cot`: TC 0.87 X HDL 0.13 TG  → scored correct
- `agent`: TC 0.87 X HDL 0.13 TG  → scored correct

